Suda Limited: ASX Spotlight Series Hong Kong

Company Presentations

by Carolyn Herbert

Suda Limited, (ASX: SUD) Chief Business Officer, Nick Woolfe provides an overview of the drug delivery company, its plans to commercialise low-risk pharmaceuticals, through its world-leading technology for reformulating drugs into oral sprays offering unique advantages
 
Suda Limited has multiple patent families covering approx. 300 widely-used off-patent drugs and its breakthrough sub-lingual spray for treatment of children with severe malaria has completed Phase III trials. With multiple oral sprays for large mainstream markets – insomnia, migraine, erectile dysfunction, chemo-induced nausea.
 
World-leading proprietary technology for reformulating drugs into high-value oral sprays, a pipeline of oral sprays offering superior profiles (eg: faster onset) than standard of care, and targeting large markets with short timelines for development and rapid value creation through collaborations or trade sales.
 
Suda anticipate first cash inflow from licensing deals in FY2016 and first royalty streams from product sales in FY2017.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.